ACM
RLAY icon

AlphaCrest Capital Management’s Relay Therapeutics RLAY Stock Holding History

AlphaCrest Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,253
Closed -$438K – 1380
2021
Q4 		$438K Buy
+14,253
New +$450K 0.02% 1148

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaCrest Capital Management's RLAY Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2022, closing a stake of 14,253 shares — an estimated $438K sold.

AlphaCrest Capital Management first reported a position in RLAY in Q4 2021 and held it in 1 quarter. The position peaked at $438K in Q4 2021. 140 funds tracked by Wall St. Rank hold RLAY as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining Relay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 14,253 Relay Therapeutics shares in Q1 2022, an estimated $438K.
  • AlphaCrest Capital Management first reported a position in Relay Therapeutics in Q4 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Relay Therapeutics position peaked at $438K in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.